Home › Companies › CAPR

Capricor Therapeutics

CAPR Rare disease Lead: NDA Submitted 11 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-17

Pipeline (2 active programs)

Deramiocel

CAP-1002

Cell

Duchenne Muscular Dystrophy NDA Submitted intravenous Nippon Shinyaku NCT01458405

StealthX vaccine

Protein Target: SARS-CoV-2 spike protein, SARS-CoV-2 nucleocapsid protein

COVID-19 Phase 1 National Institute of Allergy and Infectious Diseases

Technology platforms

StealthX

Engineered exosome platform for vaccine and therapeutic development; supports targeted RNA, protein, and small molecule delivery; focus areas include infectious diseases, monogenic diseases, and other indications

StealthX · Life Technologies Corporation

CDC-derived exosomes platform technology for therapeutic development; disease focus includes Duchenne muscular dystrophy and other diseases with high unmet medical needs

Biotech Distilled coverage (11)

2026-08-24 UPDATE: Capricor Therapeutics (CAPR) — The New Date Is November 22 🔒 Paid
2026-08-22 UPDATE: Capricor Therapeutics (CAPR) — An Activist Kicks the Door In 🔒 Paid
2026-08-15 UPDATE: Capricor Therapeutics (CAPR) — The August 22 Binary Just Got Cancelled 🔒 Paid
2026-08-14 UPDATE: Capricor Therapeutics (CAPR) — The Cash Cushion Got Thinner Nine Days Before PDUFA 🔒 Paid
2026-08-04 UPDATE: Capricor Therapeutics (CAPR) — RA Capital Just Showed Up 🔒 Paid
2026-07-30 UPDATE: Capricor Therapeutics (CAPR) — The Key Secondary Just Lost Its Star 🔒 Paid
2026-07-30 UPDATE: Capricor Therapeutics (CAPR) — 9-3 Against, and the Stock Falls Below Cash 🔒 Paid
2026-07-28 UPDATE: Capricor Therapeutics (CAPR) — The FDA Showed Its Cards, and the Stock Lost Two-Thirds 🔒 Paid
2026-07-14 UPDATE: Capricor Therapeutics (CAPR) — Signing a 138-Month Lease Two Weeks Before AdCom 🔒 Paid
2026-06-26 UPDATE: Capricor Therapeutics (CAPR) — A Third Binary Lands on the Calendar 🔒 Paid
2026-06-19 Capricor Therapeutics (CAPR) — Scientific Deep Dive for Deramiocel and the StealthX Exosome Platform 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.